2021
DOI: 10.1016/s1470-2045(20)30537-4
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Implications of all the available evidenceThis evaluation study strengthens the available evidence in the literature supporting the use of SABR in appropriately selected patients with metachronous extracranial oligometastases and resulted in routine commissioning of SABR for treating patients with oligometastatic disease by NHS England in 2019 (4).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
67
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 151 publications
(71 citation statements)
references
References 28 publications
3
67
0
1
Order By: Relevance
“…The use of stereotactic radiotherapy to treat 'oligometastases' has been commissioned by NHS England on the basis of very weak evidence, and this may well supersede the use of surgical metastasectomy [29].…”
Section: Discussionmentioning
confidence: 99%
“…The use of stereotactic radiotherapy to treat 'oligometastases' has been commissioned by NHS England on the basis of very weak evidence, and this may well supersede the use of surgical metastasectomy [29].…”
Section: Discussionmentioning
confidence: 99%
“…SBRT has been shown to achieve high rates of local control with minimal toxicity, delay the need for systemic therapy, and improve PFS. 31,32 Additionally, long-term results of the SABR-COMET randomized phase II clinical trial have demonstrated an improvement in OS at 5 years (17.7% vs. 42.3%; p = .006) with the use of SBRT in the management of oligometastatic disease (although the minority of patients had colorectal liver metastases). 33 A U.K. prospective registry reported that the use of SBRT for patients with metachronous CRC oligometastases (any site) achieved a 1-year and 2-year OS of 92% (95% CI, 86.6%-95.3%) and 80.3% (95% CI, 71.8%-86.5%), respectively.…”
Section: Stereotactic Body Radiation Therapy For Colorectal Liver Metastasesmentioning
confidence: 99%
“…33 A U.K. prospective registry reported that the use of SBRT for patients with metachronous CRC oligometastases (any site) achieved a 1-year and 2-year OS of 92% (95% CI, 86.6%-95.3%) and 80.3% (95% CI, 71.8%-86.5%), respectively. 32 Although there are no phase III randomized trials evaluating the use of SBRT in the treatment of colorectal liver metastases, several phase I and II prospective studies along with retrospective case series have demonstrated promising results in terms of OS, local control, and toxicity profile. [34][35][36][37][38][39][40][41] Median OS after SBRT for colorectal liver metastases ranges from 16 months to 32 months (Table 1); the wide range of reported outcomes is likely secondary to the heterogeneity of patients included in these studies, various lines of systemic treatment used over time, and variable tumor biology and mutation status.…”
Section: Stereotactic Body Radiation Therapy For Colorectal Liver Metastasesmentioning
confidence: 99%
“…Recently, advances in imaging and local ablative therapies have permitted the treatment of these patients with additional locoregional treatment in addition to systemic therapies, and some patients may be cured and attain long term survival. 3 This scenario has been best elucidated in prostate, kidney, lung and melanomas. 4,5 In these settings oligometastatic cancers may be treated in oligoprogressive sites continuing systemic therapy that control the remaining disease.…”
Section: Introductionmentioning
confidence: 99%